Literature DB >> 17690259

Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma.

Gudmar Thorleifsson1, Kristinn P Magnusson, Patrick Sulem, G Bragi Walters, Daniel F Gudbjartsson, Hreinn Stefansson, Thorlakur Jonsson, Adalbjorg Jonasdottir, Aslaug Jonasdottir, Gerdur Stefansdottir, Gisli Masson, Gudmundur A Hardarson, Hjorvar Petursson, Arsaell Arnarsson, Mehdi Motallebipour, Ola Wallerman, Claes Wadelius, Jeffrey R Gulcher, Unnur Thorsteinsdottir, Augustine Kong, Fridbert Jonasson, Kari Stefansson.   

Abstract

Glaucoma is a leading cause of irreversible blindness. A genome-wide search yielded multiple single-nucleotide polymorphisms (SNPs) in the 15q24.1 region associated with glaucoma. Further investigation revealed that the association is confined to exfoliation glaucoma (XFG). Two nonsynonymous SNPs in exon 1 of the gene LOXL1 explain the association, and the data suggest that they confer risk of XFG mainly through exfoliation syndrome (XFS). About 25% of the general population is homozygous for the highest-risk haplotype, and their risk of suffering from XFG is more than 100 times that of individuals carrying only low-risk haplotypes. The population-attributable risk is more than 99%. The product of LOXL1 catalyzes the formation of elastin fibers found to be a major component of the lesions in XFG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690259     DOI: 10.1126/science.1146554

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  288 in total

1.  Lack of association between LOXL1 gene polymorphisms and primary open angle glaucoma in the Saudi Arabian population.

Authors:  Khaled K Abu-Amero; Essam A Osman; Mohammad T Azad; R Rand Allingham; Michael A Hauser; Saleh A Al-Obeidan
Journal:  Ophthalmic Genet       Date:  2011-04-21       Impact factor: 1.803

2.  Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.

Authors:  Ronan S Rogers; Moyez Dharsee; Suzanne Ackloo; Jeremy M Sivak; John G Flanagan
Journal:  Mol Cell Proteomics       Date:  2011-11-29       Impact factor: 5.911

Review 3.  Current gene discovery strategies for ocular conditions.

Authors:  Priya Duggal; Grace Ibay; Alison P Klein
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

4.  Detecting protein aggregates on untreated human tissue samples by atomic force microscopy recognition imaging.

Authors:  Rhiannon Creasey; Shiwani Sharma; Jamie E Craig; Christopher T Gibson; Andreas Ebner; Peter Hinterdorfer; Nicolas H Voelcker
Journal:  Biophys J       Date:  2010-09-08       Impact factor: 4.033

5.  Scanning laser ophthalmoscopic parameters of eyes with exfoliation syndrome.

Authors:  Ali Bulent Cankaya; Emrullah Beyazyildiz
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

6.  Human behavioral informatics in genetic studies of neuropsychiatric disease: multivariate profile-based analysis.

Authors:  Cinnamon S Bloss; Kelly M Schiabor; Nicholas J Schork
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 7.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 8.  GABAA receptor polymorphisms in alcohol use disorder in the GWAS era.

Authors:  Mairi Koulentaki; Elias Kouroumalis
Journal:  Psychopharmacology (Berl)       Date:  2018-05-02       Impact factor: 4.530

9.  Interactions between lysyl oxidases and ADAMTS proteins suggest a novel crosstalk between two extracellular matrix families.

Authors:  Rohtem Aviram; Shelly Zaffryar-Eilot; Dirk Hubmacher; Hagar Grunwald; Joni M Mäki; Johanna Myllyharju; Suneel S Apte; Peleg Hasson
Journal:  Matrix Biol       Date:  2018-05-17       Impact factor: 11.583

Review 10.  The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure.

Authors:  John Kuchtey; Rachel W Kuchtey
Journal:  J Ocul Pharmacol Ther       Date:  2014-02-12       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.